Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
18 Settembre 2020 - 9:04PM
Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company
developing potentially disease-modifying AAV-based gene therapies
for patients with neurodegenerative diseases, today announced that
Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of
Prevail, will present at the virtual Oppenheimer Fall Healthcare
Life Sciences & MedTech Summit on Tuesday, September
22, 2020 at 2:30 p.m. ET.
The webcast will be available in the Events and Presentations
section of the Company's website
at ir.prevailtherapeutics.com. The webcast will be archived
for 90 days following the presentation.
About Prevail TherapeuticsPrevail is a gene
therapy company leveraging breakthroughs in human genetics with the
goal of developing and commercializing disease-modifying AAV-based
gene therapies for patients with neurodegenerative diseases. The
Company is developing PR001 for patients with Parkinson’s disease
with GBA1 mutations (PD-GBA) and neuronopathic Gaucher
disease; PR006 for patients with frontotemporal dementia
with GRN mutations (FTD-GRN); and PR004 for patients with
certain synucleinopathies.
Prevail was founded by Dr. Asa Abeliovich in 2017,
through a collaborative effort with The Silverstein
Foundation for Parkinson’s with GBA and OrbiMed, and is
headquartered in New York, NY.
Forward-Looking Statements Related to
PrevailStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Examples of
these forward-looking statements include statements concerning the
potential for Prevail’s gene therapy candidates to transform the
treatment of patients with, and slow or halt the progression of,
FTD-GRN and other neurodegenerative diseases. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. These risks and uncertainties include,
among others: Prevail’s novel approach to gene therapy makes it
difficult to predict the time, cost and potential success of
product candidate development or regulatory approval; Prevail’s
gene therapy programs may not meet safety and efficacy levels
needed to support ongoing clinical development or regulatory
approval; the regulatory landscape for gene therapy is rigorous,
complex, uncertain and subject to change; the fact that gene
therapies are novel, complex and difficult to manufacture; and
risks relating to the impact on our business of the COVID-19
pandemic or similar public health crises. These and other risks are
described more fully in Prevail’s filings with the Securities and
Exchange Commission (SEC), including the “Risk Factors” section of
the Company’s Quarterly Report on Form 10-Q for the period ended
June 30, 2020, filed with the SEC on August 11, 2020, and its other
documents subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, Prevail undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Media Contact:Mary CarmichaelTen Bridge
Communications mary@tenbridgecommunications.com 617-413-3543
Investor
Contact:investors@prevailtherapeutics.com
Grafico Azioni Prevail Therapeutics (NASDAQ:PRVL)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Prevail Therapeutics (NASDAQ:PRVL)
Storico
Da Giu 2023 a Giu 2024